知搜-全球专利检索

  1. 登录
  2. 注册
发明授权
CN105534880B 一种PVA/TA-β-CD复合水凝胶及其基质和制备方法 失效 - 权利终止

一种PVA/TA-β-CD复合水凝胶及其基质和制备方法
摘要：
本发明属于医药技术领域，通过将PVA与亲脂性TA‑β‑CD通过物理交联法制备PVA/TA‑β‑CD复合水凝胶，赋予PVA水凝胶基质高载药量及控制药物释放的新功能，PVA/TA‑β‑CD复合水凝胶的载药量和药物释放可以通过β‑CD的含量得到一定的控制。本发明的PVA/TA‑β‑CD复合水凝胶，由下述原料按重量比组成，聚乙烯醇：TA‑β‑CD为95:5～85:15，采用研磨共混法和冷冻－解冻交联技术制得。本发明通过体外对比实验表明PVA/TA‑β‑CD的复合水凝胶能有效提高疏水性药物的载药量及控制药物的释放；并且，药物/亲脂性TA‑β‑CD的包合作用还能提高药物透皮通透性并缓慢释放药物分子，作用时间持久的特点。
摘要（英）：

The invention belongs to the technical field of medicines. A PVA/TA-beta-CD composite hdyrogel is prepared through a physical cross-linking technology of PVA and lipophilic TA-beta-CD, so a PVA hydrogel matrix is endowed with new functions of high drug load and drug release control, and the drug load and the drug release of the PVA/TA-beta-CD composite hdyrogel can be controlled to a certain degree through controlling the content of beta-CD. The PVA/TA-beta-CD composite hdyrogel comprises polyvinyl alcohol and TA-beta-CD according to a weight ratio of 95:5-85:15, and is prepared through a grinding and blending technology and a refrigerating-unfreezing cross-linking technology. An in vitro contrast experiment shows that the PVA/TA-beta-CD composite hdyrogel can effectively improve the drug load of a hydrophobic drug and control the drug release; and the clathration effect of drug/lipophilic TA-beta-CD has the characteristics of improvement of the transdermal permeability of the drug, slow release of drug molecules, and lasting action time.

公开/授权文献
0/0